Nida Öztop

Nida Öztop

Auto-generated profile, based on publicly available information

Nida Öztop

Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
NONida Oztop
Nida Oztop
MVMartin Valentin Vitus
Martin Valentin Vitus
VFValentina Faihs
Valentina Faihs
CKClaudia Kugler
Claudia Kugler
TBTilo Biedermann
Tilo Biedermann
KBKnut Brockkow
Knut Brockkow
Idiopathic anaphylaxis (IA) is an unresolved concern. Hidden allergens may be relevant in IA and in non-steroidal anti-inflammatory drug hypersensitivity (NSAID-HS). To identify hidden elicitors for IA and NSAID-HS by a skin prick test (SPT; 13 allergens) and allergen-specific IgE (sIgE; 12 allergens) panel and to determine the value of each tested allergen. We retrospectively included all patients from 2018 to 2021 referred with a suspicion of IA or NSAID-HS by history in whom SPT and/or sIgE to allergens of the IA panel were performed. Patient characteristics from patients' records included comorbidities, history and symptoms of anaphylaxis, serum baseline tryptase level (sBT), total IgE level, SPT, sIgE, challenge results and final diagnoses. 134 patients (77 female; mean age 39.7±14.6 years) were included. Median sBT and total IgE levels were 4.23 μg/l and 133.5 kU/L, respectively. Allergological workup with the IA panel resulted in positive SPT and sIgE in 61 (47%) and 66 (60%) patients, respectively. In those, confirmation or exclusion of allergy, mostly by challenge, led to a definitive diagnosis in 61/134 patients (46%). SPT was most frequently positive to gluten (22.4%) and sIgE to ω5-gliadin (21.6%), which correlated with the history (r=.310 p<0.001 and r=.407 p<0.001, respectively). In 28/134 (21%) of patients with initially suspected IA or NSAID-HS, challenges confirmed occult food allergy with wheat allergy dependent on augmentation factors (WANDA) being the most frequent cause of anaphylaxis (19%). WANDA should be considered in all patients with anaphylaxis of unknown cause or after NSAID intake.

27 March 2013 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
SASibel AKIN
Sibel AKIN
GBGülistan Bahat
Gülistan Bahat
FTFatih Tufan
Fatih Tufan
BSBulent Saka
Bulent Saka
NÖNida Öztop
Nida Öztop
MKMehmet AKİF Karan
Mehmet AKİF Karan

26 August 2023 in World Allergy Organization Journal
Verified
Journal Article
Open access
OYOsman Ozan Yeğit
Osman Ozan Yeğit
AAAyşe Feyza Aslan
Ayşe Feyza Aslan
RCRaif Coşkun
Raif Coşkun
PKPelin Karadağ
Pelin Karadağ
ITİlKim Deniz Toprak
İlKim Deniz Toprak
AGAslı Gelincik
Aslı Gelincik
In 2020, World Allergy Organization (WAO) updated their diagnostic criteria for anaphylaxis, which differed as a result from the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria which were still used in the 2021 update of the European Academy of Allergy and Clinical Immunology (EAACI) anaphylaxis guideline. Our aim was to evaluate and to compare both diagnostic criteria and attempt to identify factors affecting severity of anaphylaxis. The medical records of the patients who were evaluated with suspected anaphylaxis at 3 medical centers in Türkiye between 2014 and 2021, and underwent a detailed diagnostic work-up, were analyzed retrospectively. Diagnosis of anaphylaxis was evaluated based on the WAO 2020 and EAACI 2021 and NIAID/FAAN diagnostic criteria. The severity of anaphylaxis was determined according to the WAO systemic allergic reaction grading system. Grade 5 anaphylaxis was defined as having respiratory failure, collapse/hypotension, loss of consciousness. Patients’ demographic and clinical characteristics were further analyzed depending on the severity of the reaction. One thousand and six patients were evaluated and 232 patients without a convincing diagnosis of anaphylaxis were excluded from the study. The remaining 774 patients (70.6% female, median [Inter quartile range (IQR) 25–75] age: 42 [33–52]) were included for further examination. Anaphylaxis was diagnosed in 729 (94.2%) patients meeting both criteria whereas 35 patients (4.5%) with isolated laryngeal involvement and 10 (1.3%) patients with isolated respiratory involvement were only diagnosed according to the WAO 2020 criteria. Twenty-three patients (3.0%) had a diagnosis of indolent systemic mastocytosis. Mastocytosis was related to grade 5 anaphylaxis [p = 0.022, OR (CI) = 2.9 (1.1–7.6)]. Venom allergy was a risk factor for grade 5 anaphylaxis among those for whom an eliciting allergen could be determined [p = 0.03, OR (CI) = 2.7 (1.1–6.8)]. For drug induced anaphylaxis, parenteral route of drug administration and proton pump inhibitor (PPI) allergy were considered as risk factors for grade 5 anaphylaxis [p < 0.001, OR (CI) = 6.5 (2.5–17.0); p = 0.011, OR (CI) = 10.3 (1.6–63.3)]. This multicenter study demonstrated that both criteria identified the majority of patients with anaphylaxis, but the WAO 2020 diagnostic criteria identified an additional 6%. Hymenoptera stings, PPI allergy, parenteral drug administration, and underlying mastocytosis were associated with more severe episodes.

21 December 2022 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MCMehmet Erdem Cakmak
Mehmet Erdem Cakmak
OYOsman Ozan Yeğit
Osman Ozan Yeğit
NÖNida Öztop
Nida Öztop
Introduction: Omalizumab is a humanized anti-IgE monoclonal antibody, which is effective in the treatment in patients with chronic spontaneous urticaria (CSU) who are unresponsive to antihistamine therapy. There are few studies in the literature evaluating omalizumab treatment response in patients with symptomatic dermographism (SDerm). The aim of this study was to compare the response to omalizu­mab treatment in patients with CSU and SDerm. Methods: Patients treated with omalizumab for the diagnosis of CSU and SDerm were evaluated retrospectively. Treatment response to omalizumab was evaluated with the urticaria control test (UCT). Quality of life was evaluated with the dermatology quality of life questionnaire (DLQI). Baseline UCT and DLQI were compared with UCT and DLQI after omalizumab treatment. Results: Evaluation was made of a total of 116 patients (CSU: 92, SDerm: 24), comprising 36 (31%) males and 80 (69%) females with a mean age of 38.95 ± 13.64 years. The most common accompanying comorbid disease was allergic rhinitis (n = 40, 34.5%). There was no statistically significant difference between patients with CSU and SDerm in respect of response to omalizumab treatment (p = 0.890). After omalizumab treatment, the increase in UCT and decrease in DLQI was statistically significant in all patient groups (p < 0.001; p < 0.001, respectively), patients with CSU (p < 0.001; p < 0.001, respectively) and SDerm (p < 0.001; p < 0.001, respectively). There was no statistically significant difference between baseline (before omalizumab treatment) UCT (p = 0.804) and UCT after omalizumab treatment (p = 0.933) between patients with CSU and patients with SDerm. There was no statistically significant difference between baseline (before omalizumab treatment) DLQI (p = 0.356) and DLQI after omalizumab treatment (p = 0.145) between patients with CSU and patients with SDerm. Conclusion: Omalizumab treatment improved disease control and quality of life in patients with SDerm. The findings of this study should be supported by randomized placebo-controlled studies.

21 April 2023 in Journal of Asthma
Verified
Journal Article
Closed access
MCMehmet Erdem Cakmak
Mehmet Erdem Cakmak
NÖNida Öztop
Nida Öztop
OYOsman Ozan Yeğit
Osman Ozan Yeğit
ÖÖÖzlem Özdedeoğlu
Özlem Özdedeoğlu
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.

13 June 2023 in Tuberk Toraks
Verified
Journal Article
Open access
GÇGülden Paçacı Çetin
Gülden Paçacı Çetin
SÖSeçil Kepil Özdemir
Seçil Kepil Özdemir
ÖBÖzge Can Bostan
Özge Can Bostan
NÖNida Öztop
Nida Öztop
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
SBSevim Bavbek
Sevim Bavbek
Severe asthma is associated with increased use of healthcare services, signifi-cant deterioration in the quality of life, and high disease and economic burden on patients and societies. Additional treatments are required for severe forms of asthma. Biological agents are recommended for the treatment of severe asthma. In this current status report, we aimed to evaluate the efficacy, effec-tiveness, and safety data of approved biologics; omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab, in the treatment of severe asthma and appropriate patient profiles for these biologics. Pubmed and Cochrane databases based on randomized controlled trials, posthoc analyses, meta-analyses, and real-life studies examining the efficacy and effec-tiveness of biologics in severe asthma were searched, and the results of these studies on important asthma outcomes were reviewed. Existing studies have shown that all the approved biologic agents targeting cells, receptors, and mediators involved in type 2 inflammation in the bronchial wall in severe asthma significantly reduce asthma exacerbations, reduce the need for oral corticosteroids, and improve asthma control, quality of life, and pulmonary functions. Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more approp-riate for a particular patient is an essential step in personalized treatment.